Clinical Trial Update: APG101 in Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

APG101, an investigational therapy, was studied in a Phase 1 trial for myelodysplastic syndrome; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• APG101

Snippet

Sponsor: Apogenix GmbH | Conditions: Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED